Jim Wilson’s Gemma Biotherapeutics Enters into Partnership with the Abu Dhabi Department of Health and Purehealth to Advance Global Access to Gene Therapies for Rare Diseases
Gemma plans to establish manufacturing and research centers in Abu Dhabi.
Lilly Acquires Verve Therapeutics to Advance One-time Treatments for People with High Cardiovascular Risk
Eli Lilly has acquired Verve Therapeutics, a startup co-founded by Kiran Musunuru.
Penn Spinout Dispatch Bio Emerges from Stealth Mode with $216M in Funding
Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a universal cancer treatment for solid tumors.
Penn Spinout Interius Therapeutics To Be Acquired by Kite Therapeutics for $350M
Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics .
Penn Spinout Capstan Therapeutics Acquired by AbbVie for $2.1B
AbbVie acquired Capstan, including its lead asset CPTX2309.
App that uses AI to boost caregiving for seniors wins PCI pitch competition at Philly Tech Week
PCI, Pennovation Works and Philadelphia Alliance for Capital & Technologies (PACT) hosted the “Innovate & Inspire: Research Panel & Pitch Competition” in May.
Dr. Jim Wilson’s Gene Therapy Work with Gemma Biotherapeutics Profiled by the Philadelphia Inquirer
Gemma Biotherapeutics was co-founded in 2024 by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Cerespectus and Vasowatch Join HiveBio’s Inaugural Cohort
HiveBio has selected its inaugural cohort of underrepresented biotech founders.
Cerespectus Accepted into Science Center’s Capital Readiness Program
Cerespectus was co-founded by Bryan Pukenas, MD, Associate Professor of Radiology in Penn Medicine.
MavriX Bio Announces FDA Clearance for Gene Therapy Trial
MavriX will initiate a clinical trial of a gene therapy for Angelman syndrome.